Yakult gains Japanese rights to Aeterna's perifosine
This article was originally published in Scrip
Executive Summary
Yakult Honsha has paid €6 million up front for exclusive development, commercialisation and marketing rights in Japan to Aeterna Zentaris' lead anticancer perifosine.